{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:44Z","timestamp":1787062244973,"version":"build-2736575974"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease. The introduction of therapy with biological drugs is promising, even if the efficacy is very variable. Since the response to drugs is a complex trait, identifying genetic factors associated to treatment response could help define new biomarkers for a more effective and personalized therapy. This study aimed to evaluate the potential role of polymorphisms in genes involved in PsA susceptibility as predictors of therapy efficacy. Nine polymorphisms were analyzed in a cohort of 163 PsA patients treated with TNF-i. To evaluate the treatment response, the DAPsA score was estimated for each patient. The possible association between the selected SNPs and mean values of DAPsA differences, at 22 and 54 weeks from the beginning of the treatment, were evaluated by t-test. Patients carrying the variant allele of TRAF3IP2 seemed to respond better to treatment, both at 22 and 54 weeks. This variant allele was also associated with an improvement in joint involvement. In contrast, patients carrying the IL10 variant allele showed an improvement lower than patients with the wild-type genotype at 54 weeks. Our results suggest that polymorphisms in genes associated with PsA susceptibility could also play a role in TNF-i treatment response.<\/jats:p>","DOI":"10.3390\/jpm12071094","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:21:50Z","timestamp":1656634910000},"page":"1094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of TRAF3IP2, IL10 and HCP5 Genetic Polymorphisms in the Response to TNF-i Treatment in Patients with Psoriatic Arthritis"],"prefix":"10.3390","volume":"12","author":[{"given":"Giada","family":"De Benedittis","sequence":"first","affiliation":[{"name":"Department of Biomedicine and Prevention, Section of Genetics, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, Section of Genetics, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Ciccacci","sequence":"additional","affiliation":[{"name":"UniCamillus\u2013Saint Camillus International University of Health Sciences, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-8413","authenticated-orcid":false,"given":"Paola","family":"Conigliaro","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-2825","authenticated-orcid":false,"given":"Paola","family":"Triggianese","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Fatica","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Novelli","sequence":"additional","affiliation":[{"name":"UniCamillus\u2013Saint Camillus International University of Health Sciences, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Borgiani","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, Section of Genetics, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"ref_1","first-page":"1046","article-title":"One year in review 2019: Psoriatic arthritis","volume":"38","author":"Calabresi","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-020-0886-x","article-title":"Complexities in Genetics of Psoriatic Arthritis","volume":"22","author":"Rahmati","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_3","first-page":"53","article-title":"An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis","volume":"14","author":"Chimenti","year":"2020","journal-title":"Biologics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","article-title":"A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors","volume":"36","author":"Chimenti","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jang, D.I., Lee, A.H., Shin, H.Y., Song, H.R., Park, J.H., Kang, T.B., Lee, S.R., and Yang, S.H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X20962623","article-title":"Choosing the right treatment for patients with psoriatic arthritis","volume":"12","author":"Noviani","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2014.106","article-title":"Advances in the management of psoriatic arthritis","volume":"10","author":"Olivieri","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.3389\/fimmu.2019.02726","article-title":"Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies","volume":"10","author":"Khoury","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_10","first-page":"e175","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Reolid","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/pgs-2021-0019","article-title":"Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: A meta-analysis","volume":"22","author":"Antonatos","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cge.13186","article-title":"Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases","volume":"93","author":"Tavakolpour","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","article-title":"TNF-\u03b1 gene polymorphisms: Association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis","volume":"134","author":"Murdaca","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"631603","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"iii128","DOI":"10.1093\/rheumatology\/kez107.027","article-title":"Is HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?","volume":"58","author":"David","year":"2019","journal-title":"Rheumatology"},{"key":"ref_16","first-page":"238","article-title":"The -308 TNF\u03b1 and the -174 IL-6 promoter polymorphisms associate with effective anti-TNF\u03b1 treatment in seronegative spondyloarthritis","volume":"16","author":"Fabris","year":"2016","journal-title":"Pharm. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/pgs.16.20","article-title":"Pharmacogenomics of multifactorial diseases: A focus on psoriatic arthritis","volume":"17","author":"Cascella","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: A systematic review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152232","DOI":"10.1016\/j.imbio.2022.152232","article-title":"A multilocus genetic study evidences the association of autoimmune-related genes with Psoriatic Arthritis in Italian patients","volume":"227","author":"Latini","year":"2022","journal-title":"Immunobiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/annrheumdis-2021-eular.4091","article-title":"OP0229 The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations 2021","volume":"80","author":"Coates","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ni.2479","article-title":"The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90","volume":"14","author":"Wang","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Conigliaro, P., Ciccacci, C., Politi, C., Triggianese, P., Rufini, S., Kroegler, B., Perricone, C., Latini, A., Novelli, G., and Borgiani, P. (2017). Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169956"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","article-title":"Interleukin-10: New perspectives on an old cytokine","volume":"226","author":"Mosser","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.62.6.526","article-title":"Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis","volume":"62","author":"Padyukov","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2119\/2008-00056.Liu","article-title":"Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis","volume":"14","author":"Liu","year":"2008","journal-title":"Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPG.0000000000002840","article-title":"Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease","volume":"71","author":"Bossacoma","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-9378-7-32","article-title":"The SNP at -592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development","volume":"7","author":"Cruz","year":"2012","journal-title":"Infect. Agent Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Schotte, H., Schl\u00fcter, B., Schmidt, H., Gaubitz, M., Drynda, S., Kekow, J., and Willeke, P. (2015). Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130907"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ciccacci, C., Perricone, C., Ceccarelli, F., Rufini, S., Di Fusco, D., Alessandri, C., Spinelli, F.R., Cipriano, E., Novelli, G., and Valesini, G. (2014). A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111991"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7682827","DOI":"10.1155\/2019\/7682827","article-title":"STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sj\u00f6gren\u2019s Syndrome: Association with Disease Susceptibility and Clinical Aspects","volume":"2019","author":"Colafrancesco","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/ijd.IJD_285_18","article-title":"Evaluation of HCP5 and Chemokine C Receptor type 5 Gene Polymorphisms in Indian Psoriatic Patients","volume":"64","author":"Rajesh","year":"2019","journal-title":"Indian J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"P.K. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lamana, A., L\u00f3pez-Santalla, M., Castillo-Gonz\u00e1lez, R., Ortiz, A.M., Mart\u00edn, J., Garc\u00eda-Vicu\u00f1a, R., and Gonz\u00e1lez-\u00c1lvaro, I. (2015). The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142683"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/gene.2008.1","article-title":"Variant form of STAT4 is associated with primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Korman","year":"2008","journal-title":"Genes Immun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672515","DOI":"10.3389\/fphar.2021.672515","article-title":"From Bed to Bench and Back: TNF-\u03b1, IL-23\/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:41:29Z","timestamp":1760139689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jpm12071094"],"URL":"https:\/\/doi.org\/10.3390\/jpm12071094","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}